CompletedPhase 2NCT01787487

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Naval Daver, MD
M.D. Anderson Cancer Center
Intervention
Azacitidine(drug)
Enrollment
121 enrolled
Eligibility
18 years · All sexes
Timeline
2013 – 2026

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01787487 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials